LVOX yields 53.62% · JNJ yields 2.13%● Live data
📍 LVOX pulled ahead of the other in Year 1
Combined, LVOX + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LVOX + JNJ for your $10,000?
LiveVox, Inc. develops and provides cloud contact center software for businesses. Its products include Four Clouds, an outbound voice solution that enables to manage regulatory requirements with the option of three manual and one automated outbound dialing system; bundles, including two-way messaging, outbound campaigns and compliance, speech analytics, inbound contact center, and cloud interactive voice response (IVR) solutions; inbound voice solutions, which comprise automatic call distributor, IVR, and wallboards; and blended omnichannel solutions, such as voice, email, SMS, virtual agents, and webchat. The company also offers CRM, which leverages unified customer profiles to create, facilitate, and manages digital engagement; Workforce Optimization, that helps contact centers to measure and manage agent workforce; and SpeechIQ, an AI-driven speech analytics solution to promote compliance, productivity, and quality in contact centers. It serves financial services, teleservices, healthcare, telecom, customer care, BPO, and collection industries. The company has a strategic partnership with Telarus. LiveVox, Inc. was formerly known as Tools For Health, Inc. and changed its name to LiveVox, Inc. in June 2006. The company was incorporated in 1998 and is based in San Francisco, California. LiveVox, Inc. has additional locations in Atlanta, Georgia; Bengaluru, India; Denver, Colorado; Medellin, Colombia; New York, New York; St. Louis, Missouri; and Columbus, Ohio.
Full LVOX Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.